8-K ·Filed Apr 23, 2026
8-K context-dependent: Items 5.02
Actionable Insight • Neutral
Monitor upcoming 10-Q filing for any changes in financial guidance or operations following the board refresh. The addition of an audit committee financial expert may improve financial oversight.
Final — all horizons settled through T+60d
INDP ▼ -21.90% at T+60d
NEUTRAL call ✗ call lost -21.90% · α vs SPY -26.92% · entry $3.15 → $2.46
T+1d
+4.76%
call +4.76% · α +3.98%
$3.30
settled 5mo ago
T+5d
-7.30%
call -7.30% · α -8.78%
$2.92
settled 5mo ago
T+20d
-60.95%
call -60.95% · α -65.59%
$1.23
settled 5mo ago
T+60d
-21.90%
call -21.90% · α -26.92%
$2.46
settled 2mo ago
Price Chart
Loading chart...
Executive Summary
Indaptus Therapeutics appointed two new independent directors, Tim Ruan and Dr. Yi Zhang, while Matthew McMurdo resigned. The company also formalized indemnification agreements with the new directors. These are routine governance changes with no immediate financial impact.
Key Facts
- Appointed Tim Ruan and Dr. Yi Zhang as independent directors effective April 22, 2026
- Matthew McMurdo resigned as director with no disclosed disagreements
- Both new directors received annual $30,000 retainers and indemnification agreements
- Ruan appointed to Audit Committee and qualifies as audit committee financial expert
- Zhang appointed to Nominating Committee
Financial Impact
Minimal annual cost of $60,000 in director compensation
operating expensesgeneral and administrative expenses
Risk Factors
- Potential director turnover instability with one resignation concurrent with new appointments
- Limited biotech governance experience of new directors despite strong financial and IP backgrounds
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-018608 |
| Exhibit: ex10-1.htm | 0001493152-26-018608 |
| Document: form8-k.htm | 0001493152-26-018608 |
| Document: 0001493152-26-018608-index-headers.html | 0001493152-26-018608 |
| Document: 0001493152-26-018608-index.html | 0001493152-26-018608 |
| Document: 0001493152-26-018608.txt | 0001493152-26-018608 |
13 reports for INDP
50% Hit rate best @ T+20▲ +59.35%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $2.56 $3.93 | ▼ −53.52% | ▼ −52.89% | $2.38 (+7.03%) |
Sep 4, 2026 28d ago | 424B5 | $1.85 $3.64 | ▼ −96.76% | ▼ −97.88% | $2.38 (−28.65%) |
Sep 1, 2026 4w ago | 8-K | $1.13 $2.08 | ▼ −84.07% | ▼ −83.99% | $2.38 (−110.62%) |
Aug 26, 2026 5w ago | EFFECT | $1.14 $1.17 | ▼ −2.63% | ▼ −2.75% | $2.38 (−108.77%) |
Aug 17, 2026 6w ago | S-3 | $0.9361 $1.10 | ▼ −16.97% | ▼ −17.18% | $2.38 (−154.25%) |
Aug 13, 2026 7w ago | 8-K | $1.06 $1.38 | ▲ +30.19% | ▲ +32.15% | $2.38 (+124.53%) |
Jul 20, 2026 10w ago | EFFECT | $2.46 $2.61 | ▼ −6.10% | ▼ −6.52% | $2.38 (+3.25%) |
Jun 26, 2026 13w ago | S-3 | $3.06 $2.85 | ▲ +6.86% | ▲ +8.25% | $2.38 (+22.22%) |
Jun 24, 2026 14w ago | 8-K | $3.26 $2.94 | ▲ +9.82% | ▲ +11.38% | $2.38 (+26.99%) |
May 15, 2026 20w ago | 8-K | $1.59 $1.22 | ▲ +23.27% | ▲ +24.23% | $2.38 (−49.69%) |
Showing 10 of 13
US Market Status
Market Closed — Opens Mon (65h 25m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access